Objectives: To evaluate the association between improvements in clinical and patient-reported outcomes (PROs) and improvements in workplace and household productivity in axial spondyloarthritis (axSpA) patients treated with certolizumab pegol (CZP), including ankylosing spondylitis (AS) and non-radiographic axSpA (nr-axSpA). MethOds: Analyses used Week (Wk) 24 data from the double-blind, placebo-controlled period of RAPID-axSpA (NCT01087762), for patients originally randomized to CZP. Responders and non-responders for clinical outcomes and PROs were compared in terms of change from baseline (CFB) in workplace and household productivity, assessed with the arthritis-specific Work Productivity Survey (WPS). Groups were compared using a non-parametric bootstrap-t method. LOCF was used for ASDAS and WPS outcomes; NRI for ASAS40 and PRO MCIDs. Results: 218 CZP patients entering RAPID-axSpA were analyzed at Wk24 (121 AS; 97 nr-axSpA). Patients employed at Wk24: 73.9% axSpA; 73.6% AS; 74.2% nr-axSpA. Greater improvements in workplace productivity were reported by CZP-treated axSpA patients who achieved a clinical response (presenteeism CFB [responders/non-responders]: -3.9/-1.0 for ASAS40; -4.3/-0.7 for ASDAS-MI) and reported improved physical function and less back pain (presenteeism CFB [responders/non-responders]: -3.9/0.7 for BASFI MCID; -3.5/1.3 for total back pain MCID). Clinical responses and symptom relief were also associated with improved household productivity (CFB in days with productivity reduced by ≥ 50% [responders/non-responders]: -4.8/-3.6 for ASAS40; -5.1/-2.2 for BASFI MCID; -5.6/-0.6 for ASQoL MCID) and greater social participation (CFB in family/ social/leisure days missed [responders/non-responders]: -3.3/-1.8 for ASDAS-MI; -2.9/-0.8 for total back pain MCID). Nr-axSpA responders reported numerically greater improvements in productivity than AS responders (presenteeism CFB for ASDAS-MI [responders/non-responders]: -5.5/-0.5 in nr-axSpA; -3.4/-0.9 in AS). Results should be interpreted with caution, given differences in patient number between groups, and because analyses were unadjusted for baseline productivity differences. cOnclusiOns: Achievement of clinical responses and symptom relief were associated with increased workplace and household productivity in CZP-treated axSpA patients, including AS and nr-axSpA.
Objectives: Elderly patients are at higher risk for osteoporotic (OP) fractures compared with the general population [1] , with low-trauma fractures in elderly patients associated with increased mortality risk. [2] In a high proportion of patients with an OP fracture, OP is previously undiagnosed and no OP-medication initiated [3] . This market-research aimed to assess the OP-risk in geriatric patients without OP-diagnosis. Versorgung, 56 . GMDS Jahrestagung (2011) MethOds: New patients to a German geriatric-practice without OP-diagnosis, completing a questionnaire (QU) with their physician evaluating OP-risk factors determined by the German-S3-OP-guideline[1], e.g. age, gender, BMI, were eligible. A total of 29 questions were assigned 1 or 2 points depending on OP-risk impact (total points: 0 -31). A score ≥ 3 identified "OP-suspects" who were to be referred to an orthopedist. In orthopedic-confirmed OP-cases, OP-medication was initiated. We present interim data (patients completing the QU from 10/14 to 3/15). [1] http://www.dvosteologie.org/uploads/Leitlinie%202014/DVO-Leitlinie%20Osteoporose%202014%20 Kurzfassung%20und%20Langfassung%2018.%2009.%202014.pdf Results: Among 53 patients included in the interim analysis, mean age was 78 years and 40 (76%) were post-menopausal women; 23 (43%) had co-existing diabetes and 15 (28%) chronic-renal-insufficiency. One-third (17 [32%]) had experienced ≥ 1 fracture after the age of 50. All 53 patients were identified as "OP-suspects" (mean QU-score, 6.6 points); 29 (55%) scored ≥ 7 points indicating very high OP-risk. To date, 26 patients had returned to the geriatric practice, with 12 (46%) having an orthopedicsconfirmed OP-diagnosis. cOnclusiOns: Our data suggest proactive evaluation and identification of OP is needed in the elderly population, to improve disease management including initiation of therapy as appropriate.
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PeRSiStenCe to theRaPy and the aSSoCiated RiSk of fRaCtuReS with antioSteoPoRotiC dRugS
Valentina Orlando V 1 , Francesca Guerriero F 1 , valeria Marina Monetti V 2 , Maria Claudia Punzo M 1 , Francesca Gimigliano F 3 , Giovanni Iolascon G 3 , Enrica Menditto E 1 1 University of Naples Federico II, Naples, Italy, 2 AORN Cardarelli, Naples, Italy, 3 Second University of Naples, Naples, Italy Objectives: Osteoporosis is a chronic progressive disease characterized by low bone mass and deterioration of bone structure, leading to an increate risk of fractures.The aim of this study was to investigate the determinants of non-persistence and impact of persistence on the risk of fractures. MethOds: The data used for this study were (DLQI), and Work Productivity and Activity Impairment Index (WPAI). Patients were classified as achieving: full, partial, or no benefit from treatment. Full benefit was no PsA flare, psoriasis body surface area (BSA) = 0; a "mild" rating of physician/patient global perception of PsA and all skin and joint symptoms. No benefit was a PsA flare or physician/patient global perception of PsA that remained "moderate/severe" or worsened since initiation of current therapy. Everyone else achieved partial benefit. HRQoL was described for those with partial benefit. Residual disease was defined as BSA > 0%, ≥ 1 tender or swollen joint, or ≥ 1 skin or joint symptom rated as "moderate/severe". Adjusted associations were estimated between residual disease, HRQoL, productivity and switching. Results: The sample included 398 patients; 19.6% achieved full, 49.0% partial, and 31.4% no benefit. Of those achieving partial benefit, 43.1% were female, mean (SD) age 50.1 (11.8), PsA duration in months 97.9 (91.0), BSA 8.0% (10.2%). Mean (SD) HRQoL scores for partial benefit patients were: 0.81 (0.20) EQ-5D; 27.01, (27.10) overall work impairment; 5.17 (5.16) DLQI; 11.03 (12.33) PROMIS HAQ; 0.35 (0.41) HAQ-DI. Residual disease was not associated with switching. Residual skin disease was not associated with lower EQ5D or higher WPAI scores. cOnclusiOns: A substantial proportion of patients yield partial or full benefit from biologics. In this sample, residual skin disease did not impact HRQoL or work productivity.
PMS113 eStiMating the MonetaRy value of Relief of tenniS elbow: a Contingent valuation Study of willingneSS-to-Pay
Pereira MJ 1 , Coombes BK 1 , Bisset LM 2 , Vicenzino B 1 , Connelly L 1 1 University of Queensland, Brisbane, Australia, 2 Griffith University, Gold Coast, Australia Objectives: To estimate the willingness-to-pay (WTP) for symptom relief of tennis elbow and examine whether WTP is related to injury characteristics, clinical outcomes, or other socio-demographic factors. MethOds: This cross-sectional WTP, contingent valuation study was performed alongside a randomised controlled trial comparing the addition of physiotherapy to corticosteroid injection in 165 participants with tennis elbow. The contingent value scenario constructed required participants to decide the monetary value (AUD) they would pay for a quick and non-invasive new treatment for relief of their elbow condition. Participants were told to consider that their symptoms would persist for the next 12 months if left untreated. The efficacy of this new treatment was defined as complete recovery in 50% of people treated. Two WTP approaches (bidding game and binary response) were administrated in blocks of 15 consecutive participants. For both methods, participants were randomly allocated a starting bid from values of $50, $650, $1250 or $1850. Results: The bidding game approach was performed in 73 participants. WTP values ranged from $50 -10000 [median WTP (IQR): $695 ($390, $940)]. WTP was significantly associated with an individual's gross income, greater pain and disability and a worsening condition. The binary response approach was performed in 87 participants. All participants accepted a $50 bid, while more than half accepted $650 and $1250 bids. Using this approach, participants were more likely to accept higher values if they had experienced greater pain and disability, a worsening condition and reduced pain-free grip of their affected arm. cOnclusiOns: This study examined the economic value that participants with tennis elbow ascribe to relief of their condition. The relationship between this monetary value and an individual's injury characteristics and income was also demonstrated. In future work, we propose to compare these WTP estimates with indicators of health-related quality-of-life, which were also collected during this study.
PMS114 CliniCal ReSPonSeS in Joint and Skin outCoMeS and Patient-RePoRted outCoMeS aRe aSSoCiated with inCReaSed PRoduCtivity in the woRkPlaCe and at hoMe in PSoRiatiC aRthRitiS PatientS tReated with CeRtolizuMab Pegol
Kavanaugh A 1 , Gladman D 2 , van der Heijde D 3 , Purcaru O 4 , Mease PJ 5 1 University of California, San Diego School of Medicine, La Jolla, CA, USA, 2 University of Toronto, Toronto, ON, Canada, 3 Leiden University Medical Center, Leiden, The Netherlands, 4 UCB Pharma, Brussels, Belgium, 5 Swedish Medical Center and University of Washington, Seattle, WA, USA Objectives: To evaluate the association between improvements in clinical and patient-reported outcomes (PROs) and improvements in workplace and household productivity in psoriatic arthritis (PsA) patients treated with certolizumab pegol (CZP). MethOds: Analyses used Week (Wk) 24 data from the double-blind, placebocontrolled period of RAPID-PsA (NCT01087788), for patients originally randomized to CZP. Responders and non-responders for clinical outcomes and PROs were compared in terms of change from baseline (CFB) in workplace and household productivity, assessed with the arthritis-specific Work Productivity Survey (WPS). Groups were compared using a non-parametric bootstrap-t method. LOCF was used for WPS outcomes; NRI for clinical outcomes and PRO MCIDs. Results: 273 CZP patients entering RAPID-PsA were analyzed at Wk24. 61.9% of patients were employed at Wk24. Greater improvements in workplace productivity were reported by CZP-treated patients who achieved improved joint and skin outcomes, as well as disease remission (absenteeism CFB [responders/non-responders]: -1.4/-0.5 for ACR20; -1.9/-0.4 for PASI75; -1.5/-0.6 for DAS28 remission). Clinically meaningful reductions in disability, pain and fatigue were also associated with increased workplace productivity (presenteeism CFB [responders/non-responders]: -5.4/-0.9 for HAQ-DI MCID; -3.4/-2.6 for pain MCID; -4.4/-0.9 for fatigue MCID). Clinical responses and symptom relief were also associated with improved household productivity (CFB in days with productivity reduced by ≥ 50% [responders/non-responders]: -5.8/-1.0 for ACR20; -5.5/-0.9 for PASI75; -5.1/-3.0 for DAS28 remission; -6.0/-1.9 for HAQ-DI MCID; -5.1/-1.3 for pain MCID; -5.1/-1.7 for fatigue MCID) and greater social participation (CFB in family/social/leisure days missed [responders/non-responders]: -3.0/-1.5 for PsARC; -2.9/-2.3 for fatigue MCID). Results should be interpreted with caution, given differences in patient number between groups, and because analyses were unadjusted for baseline productivity differences. cOnclusiOns: Achievement of disease remission, clinically meaningful improvements in joint and skin outcomes and symptom relief were associated with increased workplace and household productivity in PsA patients treated with CZP.
